DRUGS & SUPPLEMENTS
What is the dose of the medication you are taking?
Tareg is an antihypertensive drug. This medication is a specific antagonist of angiotensin II. It has a selective antagonistic effect on AT1-receptors, which are responsible for implementing the effects of angiotensin II.
Due to the blockade of AT1-receptors the plasma concentrations of angiotensin II increased, which may stimulate the unblocked AT2-receptors. This medicine has no agonistic activity against AT1-receptor. The affinity of Tareg for AT1-receptors in about 20 000 times higher than that of AT2-receptors.
Tareg does not inhibit ACE. This drug has no interaction and does not block other hormone receptors or ion channels important for regulation of the cardiovascular system.
This medication has no effect on total cholesterol, triglycerides, glucose and uric acid in blood plasma.
A start of antihypertensive action of Tareg after its oral administration in a single dose occurs within 2 h after administration, the maximum effect is achieved within 4-6 h.
After oral administration Tareg is rapidly absorbed from the gastrointestinal tract, the extent of absorption is characterized by individual differences. The absolute bioavailability is average 23%.
In course of treatment with this medication there were not noted changes of pharmacokinetic parameters.
When administered with food Tareg AUC decreased by 48%, with approximately 8 hours after administration of Tareg in plasma concentrations of the same in patients taking it with food and fasting. AUC decrease is not accompanied by clinically significant reduction in therapeutic effect.
When you receive Tareg 1 time / day the accumulation is expressed only slightly. The concentration of Tareg in the blood plasma of women and men were equal. The binding with plasma proteins, primarily to albumin is 94-97%.
The plasma clearance of Tareg is about 2 L / h. This medication is excreted in the feces 70% and in urine 30%, largely unchanged.
When biliary cirrhosis or biliary obstruction AUC of Tareg is increased approximately 2-fold.
A treatment of hypertension. A treatment of chronic heart failure in patients receiving conventional therapy with diuretics, digitalis preparations, as well as ACE inhibitors or beta-blockers.
Tareg is taken orally in dose 80 mg daily 1 time / day or 40 mg 2 times / day. In the absence of adequate effect the daily dose may be gradually increased. The maximum daily dose is 320 mg in 2 divided doses.
Cardiovascular system: hypotension, postural dizziness, postural hypotension.
CNS: dizziness, headache.
Digestive system: diarrhea, nausea, increased bilirubin levels.
Urinary system: rarely - renal failure, increased creatinine and BUN.
Hematopoietic system: neutropenia, a decrease in hemoglobin and hematocrit.
Allergic reactions: rarely - angioedema, rash, pruritus, serum sickness, vasculitis.
Other: fatigue, weakness, cough, sore throat, increased risk of viral infections.
Pregnancy, hypersensitivity to Tareg.
Tareg is contraindicated during pregnancy. It is not known whether Tareg is allocated to breast milk in humans. Use during lactation is not recommended.
Experimental studies have shown that this medication is excreted in breast milk of rats.
Category of the fetus by FDA - D.
When hyponatremia and / or reduction of the BCC, as well as during treatment with high doses of diuretics, Tareg, in rare cases can cause pronounced hypotension.
Before starting treatment it should be the correction of violations of water-salt metabolism.
In patients with renovascular hypertension, which developed secondary to renal artery stenosis, in the period of treatment should regularly monitor the level of urea and creatinine in serum. There is no data on the safety of patients with CC than 10 ml / min.
With great caution use in patients with impaired patency of the biliary tract.
Due to inhibition of the RAAS in patients predisposed to changes in renal function.
With use of ACE inhibitors and angiotensin receptor antagonists in patients with chronic heart failure severity of the observed oliguria and / or increase azotemia, rarely developed acute renal failure with risk of death.
Safety and efficacy of Tareg in children has not been established.
If use Tareg it is recommended a caution when driving and management mechanisms.
When this drug applied simultaneously with:
- diuretics in high doses it may developed hypotension.
- potassium-sparing diuretics, heparin, dietary supplements or salt substitutes containing potassium may develop hyperkalemia.
- indomethacin may decrease the antihypertensive action of Tareg.
- lithium carbonate, described the case of lithium toxicity.
Symptoms: hypotension, tachycardia or bradycardia.
Treatment: symptomatic therapy, dialysis is not effective.
Depending on the reaction of the Tareg after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Tareg not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Tareg addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
|No side effects||1||100.0%|
|Once in a day||2||100.0%|
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology